Top 5 Stocks to Buy Now
→ PH: Do THESE 4 things to your bank account now … (From Weiss Ratings) (Ad)tc pixel Free FDBK Stock Alerts

Feedback (FDBK) Competitors

Feedback logo
GBX 7.26 -0.04 (-0.55%)
As of 11:10 AM Eastern
Compare

FDBK vs. INHC, RENX, IQAI, DVRG, and SENS

Should you buy Feedback stock or one of its competitors? MarketBeat compares Feedback with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Feedback include Induction Healthcare Group (INHC), Renalytix (RENX), IQ-AI (IQAI), DeepVerge (DVRG), and Sensyne Health (SENS). These companies are all part of the "health information services" industry.

How does Feedback compare to Induction Healthcare Group?

Induction Healthcare Group (LON:INHC) and Feedback (LON:FDBK) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, dividends, valuation and earnings.

In the previous week, Induction Healthcare Group's average media sentiment score of 0.00 equaled Feedback'saverage media sentiment score.

Company Overall Sentiment
Induction Healthcare Group Neutral
Feedback Neutral

46.3% of Induction Healthcare Group shares are held by institutional investors. Comparatively, 34.7% of Feedback shares are held by institutional investors. 54.6% of Induction Healthcare Group shares are held by company insiders. Comparatively, 8.0% of Feedback shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Induction Healthcare Group has higher revenue and earnings than Feedback. Induction Healthcare Group is trading at a lower price-to-earnings ratio than Feedback, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Induction Healthcare Group£12.57M0.72-£5.12M-£5.54N/A
Feedback£849.62K3.74-£10.84M-£15.74N/A

Induction Healthcare Group has a net margin of -23.86% compared to Feedback's net margin of -845.25%. Induction Healthcare Group's return on equity of -14.58% beat Feedback's return on equity.

Company Net Margins Return on Equity Return on Assets
Induction Healthcare Group-23.86% -14.58% -7.32%
Feedback -845.25%-135.17%-22.99%

Induction Healthcare Group has a beta of -0.41, meaning that its share price is 141% less volatile than the broader market. Comparatively, Feedback has a beta of 0.77, meaning that its share price is 23% less volatile than the broader market.

Summary

Induction Healthcare Group beats Feedback on 8 of the 11 factors compared between the two stocks.

How does Feedback compare to Renalytix?

Renalytix (LON:RENX) and Feedback (LON:FDBK) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, valuation, risk, institutional ownership, analyst recommendations and earnings.

In the previous week, Renalytix's average media sentiment score of 0.00 equaled Feedback'saverage media sentiment score.

Company Overall Sentiment
Renalytix Neutral
Feedback Neutral

Renalytix has a beta of 1.808, meaning that its share price is 81% more volatile than the broader market. Comparatively, Feedback has a beta of 0.77, meaning that its share price is 23% less volatile than the broader market.

14.0% of Renalytix shares are held by institutional investors. Comparatively, 34.7% of Feedback shares are held by institutional investors. 5.1% of Renalytix shares are held by company insiders. Comparatively, 8.0% of Feedback shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Renalytix has a net margin of -680.00% compared to Feedback's net margin of -845.25%. Renalytix's return on equity of 274.67% beat Feedback's return on equity.

Company Net Margins Return on Equity Return on Assets
Renalytix-680.00% 274.67% -93.54%
Feedback -845.25%-135.17%-22.99%

Feedback has lower revenue, but higher earnings than Renalytix. Renalytix is trading at a lower price-to-earnings ratio than Feedback, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Renalytix£3.30M2.48-£109.93M-£4.00N/A
Feedback£849.62K3.74-£10.84M-£15.74N/A

Summary

Feedback beats Renalytix on 6 of the 11 factors compared between the two stocks.

How does Feedback compare to IQ-AI?

IQ-AI (LON:IQAI) and Feedback (LON:FDBK) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, analyst recommendations, institutional ownership and risk.

34.7% of Feedback shares are held by institutional investors. 66.0% of IQ-AI shares are held by insiders. Comparatively, 8.0% of Feedback shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, IQ-AI's average media sentiment score of 0.00 equaled Feedback'saverage media sentiment score.

Company Overall Sentiment
IQ-AI Neutral
Feedback Neutral

IQ-AI has a beta of 2.25, suggesting that its share price is 125% more volatile than the broader market. Comparatively, Feedback has a beta of 0.77, suggesting that its share price is 23% less volatile than the broader market.

IQ-AI has higher earnings, but lower revenue than Feedback.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IQ-AI£538.19K3.30N/AN/AN/A
Feedback£849.62K3.74-£10.84M-£15.74N/A

IQ-AI has a net margin of -77.52% compared to Feedback's net margin of -845.25%. Feedback's return on equity of -135.17% beat IQ-AI's return on equity.

Company Net Margins Return on Equity Return on Assets
IQ-AI-77.52% -140.75% -22.03%
Feedback -845.25%-135.17%-22.99%

Summary

Feedback beats IQ-AI on 5 of the 9 factors compared between the two stocks.

How does Feedback compare to DeepVerge?

DeepVerge (LON:DVRG) and Feedback (LON:FDBK) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, media sentiment, valuation, dividends, profitability, risk and analyst recommendations.

DeepVerge has a beta of 1.07, suggesting that its share price is 7% more volatile than the broader market. Comparatively, Feedback has a beta of 0.77, suggesting that its share price is 23% less volatile than the broader market.

DeepVerge has higher revenue and earnings than Feedback. Feedback is trading at a lower price-to-earnings ratio than DeepVerge, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
DeepVerge£12.41M0.00-£2.46M-£0.01N/A
Feedback£849.62K3.74-£10.84M-£15.74N/A

DeepVerge has a net margin of -19.81% compared to Feedback's net margin of -845.25%. DeepVerge's return on equity of -10.27% beat Feedback's return on equity.

Company Net Margins Return on Equity Return on Assets
DeepVerge-19.81% -10.27% -5.56%
Feedback -845.25%-135.17%-22.99%

4.2% of DeepVerge shares are owned by institutional investors. Comparatively, 34.7% of Feedback shares are owned by institutional investors. 9.5% of DeepVerge shares are owned by insiders. Comparatively, 8.0% of Feedback shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, DeepVerge's average media sentiment score of 0.00 equaled Feedback'saverage media sentiment score.

Company Overall Sentiment
DeepVerge Neutral
Feedback Neutral

Summary

DeepVerge beats Feedback on 8 of the 10 factors compared between the two stocks.

How does Feedback compare to Sensyne Health?

Sensyne Health (LON:SENS) and Feedback (LON:FDBK) are both small-cap health information services industry companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, media sentiment, profitability, valuation, earnings and institutional ownership.

Sensyne Health has a net margin of 0.00% compared to Feedback's net margin of -845.25%. Sensyne Health's return on equity of 0.00% beat Feedback's return on equity.

Company Net Margins Return on Equity Return on Assets
Sensyne HealthN/A N/A N/A
Feedback -845.25%-135.17%-22.99%

34.7% of Feedback shares are owned by institutional investors. 8.0% of Feedback shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Sensyne Health has higher revenue and earnings than Feedback. Feedback is trading at a lower price-to-earnings ratio than Sensyne Health, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sensyne Health£7.81M0.00N/A-£22.10N/A
Feedback£849.62K3.74-£10.84M-£15.74N/A

In the previous week, Sensyne Health's average media sentiment score of 0.00 equaled Feedback'saverage media sentiment score.

Company Overall Sentiment
Sensyne Health Neutral
Feedback Neutral

Summary

Sensyne Health beats Feedback on 5 of the 8 factors compared between the two stocks.

Get Feedback News Delivered to You Automatically

Sign up to receive the latest news and ratings for FDBK and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

FDBK vs. The Competition

Export
MetricFeedbackHealth Information Services IndustryMedical SectorLON Exchange
Market Cap£3.18M£347.89M£6.45B£2.78B
Dividend Yield4.56%5.60%2.69%6.16%
P/E Ratio-0.46250.8724.92365.72
Price / Sales3.74132.06528.8186,253.69
Price / Cash1.1247.1444.8227.85
Price / Book0.137.3310.797.92
Net Income-£10.84M-£22.78M£3.56B£5.89B
7 Day Performance-2.22%-0.92%1.67%-0.87%
1 Month Performance-19.33%1.59%0.43%-0.76%
1 Year Performance-48.80%-10.58%32.84%70.67%

Feedback Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
FDBK
Feedback
N/AGBX 7.26
-0.5%		N/A-51.6%£3.18M£849.62KN/A24
INHC
Induction Healthcare Group
N/AGBX 9.75
flat		N/A+0.0%£9.00M£12.57MN/A74
RENX
Renalytix
N/AGBX 1.87
-1.6%		N/A-74.2%£8.17M£3.30MN/A102
IQAI
IQ-AI
N/AGBX 0.80
flat		N/A+0.0%£1.77M£538.19KN/A6
DVRG
DeepVerge
N/AN/AN/AN/A£1.14M£12.41MN/A73

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:FDBK) was last updated on 6/23/2026 by MarketBeat.com Staff.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
The roadshow starts Monday. This stock isn't ready.
The SpaceX roadshow kicks off June 8. Goldman Sachs, the lead underwriter, will present the full S-1 to the wo...
Behind the Markets | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...
Stansberry Research | Sponsoredtc pixel
Trump just signed it
A recent policy development is drawing attention from income-focused investors. According to one analyst, c...
Investors Alley | Sponsoredtc pixel
SpaceX is chump change compared to Elon’s $20T ‘iPhone’
Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...
StocksToTrade | Sponsoredtc pixel